Vivimed gets DGHI nod to make, market Favipiravir | India News


HYDERABAD: Pharma player Vivimed Labs Ltd on Monday said it has received approval from the director general of health services (DGHI), government of India, to manufacture and market Favipiravir tablets of 200mg and 400mg strengths in the Indian market.
The Hyderabad-based niche specialty chemicals and pharmaceuticals player said it will be marketing the oral anti-viral drug under its own brand Favulous.
Favipiravir, which has been approved for treating patients with mild to moderate Covid-19 disease in several countries.
Commenting on the rollout, Ramesh Krishnamurthy, CEO, Vivimed Labs Ltd, said, “With a huge spike in Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching Favulous at a competitive price to make the drug accessible to more patients, thereby ensuring good health and reducing their financial burden. This is in line with Vivimed’s commitment to be at forefront in India’s fight against Covid-19.”
The company also said it will work closely with various governments and the medical community to ensure availability of the drug to patients across the country.